Overcoming drug resistance in glioblastoma: new options in sight?
作者信息
Kopecka Joanna, Riganti Chiara
机构信息
Department of Oncology, University of Torino, Torino 10126, Italy.
出版信息
Cancer Drug Resist. 2021 Jun 19;4(2):512-516. doi: 10.20517/cdr.2021.03. eCollection 2021.
Abstract
摘要
相似文献
1
Overcoming drug resistance in glioblastoma: new options in sight?
Cancer Drug Resist. 2021 Jun 19;4(2):512-516. doi: 10.20517/cdr.2021.03. eCollection 2021.
2
Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.
Int J Mol Sci. 2022 Feb 2;23(3):1711. doi: 10.3390/ijms23031711.
3
A vasculature-centric approach to developing novel treatment options for glioblastoma.
Expert Opin Ther Targets. 2021 Feb;25(2):87-100. doi: 10.1080/14728222.2021.1881062. Epub 2021 Mar 1.
4
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Anticancer Agents Med Chem. 2010 Sep;10(7):520-33. doi: 10.2174/187152010793498627.
5
Overcoming the Challenges in the Treatment of Glioblastoma via Nanocarrier- based Drug Delivery Approach.
Curr Pharm Des. 2021;27(45):4539-4556. doi: 10.2174/1381612827666210603152056.
6
Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
Curr Drug Targets. 2014;15(10):931-42.
7
Overcoming TRAIL Resistance for Glioblastoma Treatment.
Biomolecules. 2021 Apr 14;11(4):572. doi: 10.3390/biom11040572.
8
Overcoming therapeutic resistance in glioblastoma: the way forward.
J Clin Invest. 2017 Feb 1;127(2):415-426. doi: 10.1172/JCI89587.
9
Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab.
Saudi Pharm J. 2021 Nov;29(11):1289-1302. doi: 10.1016/j.jsps.2021.09.015. Epub 2021 Oct 5.
10
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
Drug Resist Updat. 2018 Sep;40:17-24. doi: 10.1016/j.drup.2018.10.001. Epub 2018 Oct 30.
引用本文的文献
1
A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.
Front Oncol. 2022 Sep 23;12:950167. doi: 10.3389/fonc.2022.950167. eCollection 2022.
本文引用的文献
1
Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway.
Cancer Drug Resist. 2020 Jun 16;3(3):334-355. doi: 10.20517/cdr.2020.17. eCollection 2020.
2
Drug resistance in glioblastoma: are persisters the key to therapy?
Cancer Drug Resist. 2020 Aug 7;3(3):287-301. doi: 10.20517/cdr.2020.29. eCollection 2020.
3
Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma.
Cancer Drug Resist. 2020 Aug 7;3(3):623-635. doi: 10.20517/cdr.2020.33. eCollection 2020.
4
Novel approaches to combat chemoresistance against glioblastomas.
Cancer Drug Resist. 2020 Aug 21;3(4):686-698. doi: 10.20517/cdr.2020.38. eCollection 2020.
5
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas.
Cancer Drug Resist. 2021 Mar 19;4(1):1-16. doi: 10.20517/cdr.2020.61. eCollection 2021.
6
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
Sci Rep. 2020 Oct 28;10(1):18445. doi: 10.1038/s41598-020-75477-9.
7
Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapy.
Cancer Drug Resist. 2020;3(3):401-414. doi: 10.20517/cdr.2020.25. Epub 2020 Aug 21.
8
Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma.
J Neuropathol Exp Neurol. 2020 Oct 1;79(10):1031-1037. doi: 10.1093/jnen/nlaa102.
9
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
Front Immunol. 2020 Jul 17;11:1402. doi: 10.3389/fimmu.2020.01402. eCollection 2020.
10
Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma.
Front Oncol. 2020 May 15;10:798. doi: 10.3389/fonc.2020.00798. eCollection 2020.
Zotero 插件